Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy

被引:0
作者
A. Sivaraman
G. Ordaz Jurado
X. Cathelineau
Eric Barret
P. Dell’Oglio
S. Joniau
M. Bianchi
A. Briganti
M. Spahn
P. Bastian
J. Chun
P. Chlosta
P. Gontero
M. Graefen
R. Jeffrey Karnes
G. Marchioro
B. Tombal
L. Tosco
H. Henk van der Poel
R. Sanchez-Salas
机构
[1] Institute Mutualiste Monsouris,Department of Urology
[2] EMPaCT Database,undefined
来源
World Journal of Urology | 2016年 / 34卷
关键词
High-risk prostate cancer; Radical prostatectomy; Charlson comorbidity index; Survival benefit;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1367 / 1372
页数:5
相关论文
共 202 条
  • [1] Heidenreich A(2011)EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 61-71
  • [2] Bellmunt J(2014)Robot-assisted radical prostatectomy: inching toward gold standard Urol Clin N Am 41 473-484
  • [3] Bolla M(2015)Robotics in urological surgery: evolution, current status and future perspectives Actas Urol Esp 39 9-10
  • [4] Joniau S(2013)The impact of robotic surgery in urology Actas Urol Esp 37 652-657
  • [5] Mason M(2011)Predicting 15-year prostate cancer specific mortality after radical prostatectomy J Urol 185 869-875
  • [6] Matveev V(2010)Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era BJU Int 106 37-43
  • [7] Mottet N(2012)Identifying the best candidate or radical prostatectomy among patients with high-risk prostate cancer Eur Urol 61 584-592
  • [8] Schmid HP(2011)Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer Cancer 117 2883-2891
  • [9] van der Kwast T(2011)A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988–2006 Eur Urol 59 88-95
  • [10] Wiegel T(2010)Comparative risk adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer Cancer 116 5226-5234